Unknown

Dataset Information

Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study.


ABSTRACT:

Background

The efficacy and safety of pazopanib in patients diagnosed with metastatic renal cell carcinoma (mRCC) have been demonstrated by a Chinese subgroup analysis of the COMPARZ (Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma) trial. However, the real-world data are still unknown. This single-center, retrospective study was designed to verify the real-world effects of pazopanib in Chinese patients with mRCC.

Methods

Patients with mRCC and a clinical decision to initiate pazopanib as first-line therapy were eligible. The primary endpoint was progression-free survival (PFS), with overall survival (OS), objective response rate (ORR), and safety being evaluated as secondary endpoints. The effectiveness according to the

SUBMITTER: Chen J 

PROVIDER: S-EPMC8039632 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature